Is today’s capital discipline strengthening biotech at the expense of future growth? Today, investors are favoring later-stage, de-risked assets because they are more likely to succeed and to succeed sooner. So, the returns are easier to model. But have we sufficiently weighed the unintended consequence? If we provide less capital to early-stage science, we might … Continue reading Biotech Investment Trend and Opportunity Cost
Lilly Acquires 4E Tx – Adds to Non-Opioid Pain Management Assets
Eli Lilly acquired 4E Therapeutics this week for an undisclosed amount. 4E Therapeutics is based on Austin, TX, and is dedicated to developing innovative and novel treatments for neuropathic pain. 4E Therapeutics Pipeline CandidateIndicationDevelopment Stage4ET1103Neuropathic PainPhase I4ET2124Migraine PainIND EnablingMNK-EIF4EAcute PainDiscovery Lilly previously paid cash for SiteOne Therapeutics, a South-San-Francisco company developing potent and selective non-opioid … Continue reading Lilly Acquires 4E Tx – Adds to Non-Opioid Pain Management Assets
A Molecule and a Dream: But is it Operational?
What makes a promising scientific asset truly fundable is whether it is operational, whether the path from milestone to milestone is robust. Signs of a Reliable Investment (Image Creation - ChatGPT) Designing Biotech Financial Models for Series B Success from WorldPharmaToday reframes what gets scrutinized in biotech financial models. Here are the key takeaways - … Continue reading A Molecule and a Dream: But is it Operational?
Lilly acquires Ajax Therapeutics for $2.3B cash
Eli Lilly is acquiring Ajax Therapeutics by paying up to $2.3B cash, composed of an upfront and milestone payments. Image Credit: ChatGPT
Big Pharma Bets for the Next Decade
Follow the spending 2025 R&D Expenditure against 2025 Revenue and 2024 Expenditure Reference: Top 10 pharma R&D budgets in 2025
Geopolitics and Monetary Policy: Why Big Pharma Should Wait & See
Global Tensions as a Backdrop Uncertainty, not Inflation may direct the Fed's next move. As global markets react to ripples from the Iran conflict, the Fed is expected to keep current interest rates steady. Traditional economic signals are harder to interpret in the wake of geopolitical shocks; reflexive decision making can do more harm than … Continue reading Geopolitics and Monetary Policy: Why Big Pharma Should Wait & See
Insidious CMC Risks in Regulatory Filings
As the FDA notes, many IND delays can be tied to CMC challenges. Quite often, warning signs are visible - analytical methods that are good enough but hard to scale- process steps that rely on the skills of an operator or one site- issues on stability or delivery that are shelved into future work.Such considerations … Continue reading Insidious CMC Risks in Regulatory Filings
Biotech Sector, Investor confidence, Cautious optimism
After being stagnant since 2022, the Biotech sector now shows renewed growth. Biotech ETF (XBI) has outperformed the S&P 500. So, perhaps it's time for cautious optimism for investors, acquirers, and innovators. Quiet Comeback Biotech ETF has grown 5% in the last month compared to the 0.2% growth of the S&P 500. This might not … Continue reading Biotech Sector, Investor confidence, Cautious optimism
Lilly Scoops up Adverum for $261M, with CVR and Loan
Adverum Biotechnologies (ADVM:NASDAQ) is being acquired by Eli Lilly and Company for $261M. While the acquisition proposes a transfer of $261M from Lilly to Adverum's stockholders, it is structured through a milestone payment and a bridge-loan. Payment Snapshot Upfront - $3.56/shareCVR - max $8.91/share contingent upon FDA approval and target sales of Ixo-vec.Bridge Loan - … Continue reading Lilly Scoops up Adverum for $261M, with CVR and Loan
Pfizer’s Big Beautiful Deal: Cheaper Drugs, US jobs, Tariff Relief
Pfizer has signed a momentous agreement with the US Federal government. Here's a snippet of what Pfizer gets and what we get (to be instituted in 2026): Quick Outline Pfizer will adhere to the most favored nation (MFN) pricing for all sales to Medicaid. So, Medicaid, usually the biggest customer to big pharma, will pay … Continue reading Pfizer’s Big Beautiful Deal: Cheaper Drugs, US jobs, Tariff Relief
BK talks Biopharm 